Effects of risperidone on aberrant behavior of persons with developmental disabilities: I. A double-blind crossover study using multiple measures

Am J Ment Retard. 2001 Nov;106(6):525-38. doi: 10.1352/0895-8017(2001)106<0525:EOROAB>2.0.CO;2.


The efficacy of the atypical antipsychotic risperidone was evaluated in the treatment of aberrant behavior (e.g., aggression, self-injury) in 20 individuals with developmental disabilities. A double-blind, crossover design was used to compare risperidone with placebo in a 22-week trial with a 6-month follow-up phase. Based on a 50% reduction in mean Aberrant Behavior Checklist--Community total scores, 50% of the participants were identified as responders. Naturalistic observations of a subset of five individuals showed that for 4 out of 5 participants, risperidone was effective in reducing aberrant behavior. Side effects included weight gain (84% of participants) and sedation (40% of participants). The advantages of conducting a comprehensive analysis of the effects of medication on aberrant behavior are discussed.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aggression / drug effects*
  • Child
  • Cross-Over Studies
  • Dose-Response Relationship, Drug
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Humans
  • Intellectual Disability / diagnosis
  • Intellectual Disability / drug therapy*
  • Intellectual Disability / psychology
  • Male
  • Middle Aged
  • Risperidone / adverse effects
  • Risperidone / therapeutic use*
  • Self-Injurious Behavior / diagnosis
  • Self-Injurious Behavior / drug therapy*
  • Self-Injurious Behavior / psychology
  • Treatment Outcome


  • Risperidone